Phase 2Completed
CM-101 in NASH Patients - The SPLASH Study
Phase 2A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of CM-101 in Patients With Non-Alcoholic Steatohepatitis (NASH)
- Sponsor
- ChemomAb Ltd. (Industry)
- Enrolment
- 23 enrolled
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- 5 mg/kg CM-101; Placebo
- Ages
- adults, older adults
- Registry
- NCT05824156
From the registry
This phase 2a study is a multi-center, double-blind randomized, placebo-controlled study. The study is designed to determine the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) patients with stage 1c, 2 or 3 fibrosis. The patients will be randomized to 1 of 2 treatment groups: 5 mg/kg CM-101 or placebo.
Primary outcomes
- Safety-related endpoints - Treatment emergent adverse events (TEAEs)